Short answer
Maze Therapeutics, Inc. (MAZE) filed its Q1 2026 10-Q quarterly report on May 12, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $20M with net income of −$24M.
Q1 2026 key financials · XBRL
- Revenue
- $20M
- Net income
- −$24M
- +26.2% YoY
- Operating margin
- -132.8%
- EPS (diluted)
- −$0.45
- +60.9% YoY
Source: XBRL data from the Maze Therapeutics, Inc. (MAZE) Q1 2026 10-Q on SEC EDGAR. USD.
Maze Therapeutics, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New $200.0 million Hercules term facility triggered secured-debt and covenant risks
- Debt secured by substantially all assets except intellectual property, with maturity February 1, 2031
- Prime-linked interest floors of 7.95%–9.25% expose cash flow to higher borrowing costs
- $362.9 million cash, equivalents and marketable securities expected to fund operations at least one year
- April 2026 offering raised approximately $144.7 million but diluted existing stockholders through 5,540,000 shares and 850,000 warrants
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Maze Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.